US drugmaker ICN Pharmaceuticals is to set up a medical center inSwansea, Wales, UK, to conduct research combining lasers and pharmaceuticals to develop ways of using drug and laser therapy in the treatment of skin disease and cancer.
The new center will be based at the Swansea Technium, a project intended to attract international R&D projects with high growth potential. ICN already owns SLS Biophile, which was acquired last year and is based in the Welsh town of Lanelli.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze